SAN DIEGO, May 18, 2004 (PRIMEZONE) -- Cell Bio-Systems, Inc. (Pink Sheets:CBSI), a biotechnology company seeking to manufacture and distribute patented, disposable technologies for cosmetic surgery, biopsy, orthopedic surgery and other living tissue procedures, announced today that it has named Dr. Robert E. Peters as the company's new Director of Research and Development. In this capacity, Dr. Peters will manage all research, design and development aspects of the company's innovative tissue transfer products, which are expected to enter full commercial production later this year.
Dr. Peters is a widely regarded biologist, biochemist, physician and medical researcher. A San Diego-area physician in private practice since 1998, his extensive research background includes work in the areas of virology, cancer immunology, cellular and molecular endocrinology, and anesthesiology, to name a few. He has published numerous academic journal articles on the findings of his research relating to biochemistry.
During his tenure with The Immune Response Corporation (founded by Jonas Salk) (Nasdaq:IMNR), Dr. Peters created the firm's serology and biochemistry sections; developed clinical protocols; established initial AIDS vaccine product trials; and served as the company's general safety officer. Dr. Peters previously managed the immunochemistry department at Cytotech, Inc., where he directed research and development of commercial infectious disease diagnostic kits; developed purification methods for viral proteins; developed an HIV Western blot detection assay, and managed many aspects of manufacturing and quality control.
A member of the San Diego County GERM Commission, Dr. Peters earned his M.D. from Loma Linda University School of Medicine, his Ph.D. in biochemistry from the University of California, Riverside, and his B.S. in biology from the University of Arizona.
"The addition of Dr. Peters is a major coup for our company and speaks volumes as to the soundness of our model," said Marc Pilkington, president and CEO of Cell Bio-Systems. "With a physician and researcher of his caliber now behind our R&D efforts, we are all the more confident in the incredible potential for the future of Cell Bio-Systems' products."
About Cell Bio-Systems
Based in San Diego, California, Cell Bio-Systems is the exclusive licensee of two patented syringe connection products that it plans to adapt as disposable devices for liposuction and other Living Tissue Management(tm) procedures. The company is developing an affordable, disposable product line that will fill this void in the cosmetic surgery and living tissue marketplace. The company's patented, groundbreaking technology will increase patient safety and enhance procedural outcomes. Most notably, Cell Bio-Systems devices can be adapted for a variety of procedures, ranging from fat transfers to biopsies to stem cell research. The company ultimately will develop a complete living tissue management system. For more information, please visit www.cellbiosystems.com.
Legal Notice Regarding Forward-Looking Statements: "Forward-looking statements", as defined in the Private Securities Litigation Reform Act of 1995, may be included in this news release. These statements relate to future events or our future financial performance. These statements are only predictions and may differ materially from actual future results or events. CBSI disclaims any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise. There are important risk factors that could cause actual results to differ from those contained in forward-looking statements, including, but not limited to risks associated with changes in general economic and business conditions (including in the information technology and financial information industry), actions of our competitors, the extent to which we are able to develop new services and markets for our services, the time and expense involved in such development activities, the level of demand and market acceptance of our services, and changes in our business strategies.